CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology announced positive Phase 2 results from CORE-008 Cohort CX evaluating intravesical cretostimogene combined with gemcitabine in high-risk BCG-exposed and BCG-unresponsive bladder cancer patients. The trial demonstrated high complete response rates (85.7-92.3%), high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months, with a favorable safety profile and no Grade 3+ treatment-related adverse events.